Quoin Pharmaceuticals Ltd.
QNRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671502
In the last 90 days, Quoin Pharmaceuticals Ltd. insiders filed 4 open-market purchases and 0 sales; 19 institutions reported holding it in 13F filings for Q2 2026, worth $6.29M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Quoin Pharmaceuticals Ltd. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −2 vs. Q1 2026
- Shares held
- 1.30M
- +114.7K (+9.7%) vs. Q1 2026
- Total value
- $6.29M
- −$1.53M (−19.6%) vs. Q1 2026
- New holders
- 1
- 9 more added
- Sold out
- 3
- 3 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting QNRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 19 | $6.29M |
| Q1 2026 | 21 | $7.82M |
| Q4 2025 | 18 | $12.2M |
| Q3 2025 | 4 | $10.7K |
| Q2 2025 | 6 | $23.4K |
| Q1 2025 | 10 | $90.2K |
| Q4 2024 | 14 | $1.01M |
| Q3 2024 | 7 | $82.2K |
| Q2 2024 | 10 | $127.7K |
| Q1 2024 | 8 | $183.2K |
| Q4 2023 | 3 | $105.6K |
| Q3 2023 | 3 | $7.21K |
| Q2 2023 | 2 | $24.0K |
| Q1 2023 | 4 | $81.1K |
| Q4 2022 | 4 | $52.0K |
| Q3 2022 | 7 | $272.0K |
| Q2 2022 | 8 | $321.0K |
| Q1 2022 | 6 | $419.0K |
| Q4 2021 | 7 | $383.0K |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Quoin Pharmaceuticals Ltd.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 355 | $1.72K | 0.00% | +353+17,650.0% | Added |
| GAMMA Investing LLC | 439 | $2.13K | 0.00% | −1,281−74.5% | Reduced |
| Rhumbline Advisers | 2,332 | $11.3K | 0.00% | +811+53.3% | Added |
| UBS Group AG | 6,772 | $32.8K | 0.00% | +4,260+169.6% | Added |
| Morgan Stanley | 8,000 | $38.7K | 0.00% | +4,000+100.0% | Added |
| XTX Topco Ltd | 15,006 | $72.6K | 0.00% | +15,006 | New |
| Birchview Capital, LP | 20,000 | $96.8K | 0.05% | 00.0% | Unchanged |
| Barclays PLC | 21,469 | $103.9K | 0.00% | +20,169+1,551.5% | Added |
| Velan Capital Investment Management LP | 32,372 | $156.7K | 0.10% | −52,477−61.8% | Reduced |
| Boothbay Fund Management, LLC | 59,838 | $289.6K | 0.01% | 00.0% | Unchanged |
| AIGH Capital Management LLC | 70,000 | $338.8K | 0.03% | +19,000+37.3% | Added |
| Soleus Capital Management, L.P. | 72,730 | $352.0K | 0.01% | 00.0% | Unchanged |
| Standard Life Aberdeen plc | 75,000 | $363.0K | 0.00% | 00.0% | Unchanged |
| Woodline Partners LP | 76,446 | $370.0K | 0.00% | −3,136−3.9% | Reduced |
| SummitTX Capital, L.P. | 100,300 | $485.5K | 0.01% | 00.0% | Unchanged |
| Millennium Management LLC | 112,323 | $543.6K | 0.00% | +36,076+47.3% | Added |
| Stonepine Capital Management, LLC | 199,486 | $965.5K | 0.74% | +146,026+273.2% | Added |
| Ikarian Capital, LLC | 211,538 | $1.02M | 0.17% | 00.0% | Unchanged |
| Dauntless Investment Group, LLC | 214,987 | $1.04M | 1.80% | +18,395+9.4% | Added |
| Centiva Capital, LP | 0 | $0 | 0.00% | −60,000−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −32,519−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −11−100.0% | Sold out |